Humacyte Prices $50M Stock Offering at $1.05 Per Share with 30-Day Green Shoe
HUMA•Humacyte priced a $1.05 per share public offering of 47.62 million common shares, raising gross proceeds of $50 million and granting underwriters a 30-day option for an additional 7.14 million shares. Net proceeds will fund the commercialization of Symvess, a planned hemodialysis BLA supplement, pipeline development, and general corporate purposes.
1. Offering Pricing Details
Humacyte concluded an underwritten public offering of 47,619,048 common shares at $1.05 each, generating $50 million in gross proceeds before fees.
2. Overallotment Option
The company granted underwriters a 30-day option to purchase up to 7,142,857 additional shares at the same price, potentially raising an extra $7.5 million.
3. Planned Use of Proceeds
Net proceeds are earmarked to support the commercialization of Symvess, the planned filing of a hemodialysis BLA supplement, development of pipeline candidates, and for working capital and general corporate purposes.
4. Closing and Conditions
The offering is scheduled to close on or about June 12, 2026, subject to satisfaction of customary closing conditions.
